Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

1,020

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2008

Conditions
Osteoarthritis
Interventions
DRUG

Naproxcinod 375 mg bid

Naproxcinod 375 mg bid

DRUG

Naproxcinod 750 mg bid

Naproxcinod 750 mg bid

DRUG

Naproxen 500 mg bid

Naproxen 500 mg bid

DRUG

placebo

placebo

Trial Locations (73)

Unknown

Chandler

Tempe

Tucson

Little Rock

Anaheim

Encino

Foothill Ranch

Orange

Rancho Mirage

Riverside

Denver

Waterbury

Boca Raton

Brooksville

DeLand

Jacksonville

Largo

Ocala

Pinellas Park

St. Petersburg

Tampa

Athens

Atlanta

Marietta

Chicago

Rockford

Prairie Village

Wichita

Erlanger

Louisville

Baton Rouge

Owings Mills

Wellesley Hills

Ann Arbor

Brooklyn Center

Edina

Florissant

St Louis

Rochester

Asheville

Charlotte

Concord

Raleigh

Salisbury

Winston-Salem

Beachwood

Columbus

Marion

Clinton

Altoona

Bensalem

Duncansville

Philadelphia

West Reading

Anderson

Clinton

Goose Creek

Greer

Mt. Pleasant

Cordova

Jackson

Kingsport

Memphis

Dallas

Garland

Houston

Nederland

San Antonio

Salt Lake City

Norfolk

Roanoke

Virginia Beach

Lakewood

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NicOx

INDUSTRY

NCT00504127 - Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter